CN113710665A - 半乳糖凝集素-3的小分子抑制剂 - Google Patents

半乳糖凝集素-3的小分子抑制剂 Download PDF

Info

Publication number
CN113710665A
CN113710665A CN202080027684.8A CN202080027684A CN113710665A CN 113710665 A CN113710665 A CN 113710665A CN 202080027684 A CN202080027684 A CN 202080027684A CN 113710665 A CN113710665 A CN 113710665A
Authority
CN
China
Prior art keywords
disorders
compound
alkyl
phenyl
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027684.8A
Other languages
English (en)
Chinese (zh)
Inventor
刘春健
冯建新
P·德瓦斯塔尔
N·穆鲁吉桑
B·A·埃尔斯沃思
A·雷盖罗-伦
S·J·奈良
P·R·雅拉加姆
M·潘达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN113710665A publication Critical patent/CN113710665A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080027684.8A 2019-04-10 2020-04-08 半乳糖凝集素-3的小分子抑制剂 Pending CN113710665A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831753P 2019-04-10 2019-04-10
US62/831,753 2019-04-10
PCT/US2020/027203 WO2020210308A1 (en) 2019-04-10 2020-04-08 Small molecule inhibitors of galectin-3

Publications (1)

Publication Number Publication Date
CN113710665A true CN113710665A (zh) 2021-11-26

Family

ID=70476468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027684.8A Pending CN113710665A (zh) 2019-04-10 2020-04-08 半乳糖凝集素-3的小分子抑制剂

Country Status (6)

Country Link
US (1) US12269819B2 (https=)
EP (1) EP3953349A1 (https=)
JP (1) JP7577682B2 (https=)
KR (1) KR102890853B1 (https=)
CN (1) CN113710665A (https=)
WO (1) WO2020210308A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
EP4149939A1 (en) * 2020-05-11 2023-03-22 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
ES3014851T3 (en) 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) * 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) * 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US9021050B2 (en) 2012-08-31 2015-04-28 Yume, Inc. Network service system and method with off-heap caching
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−3のガラクトシド阻害剤及び肺線維症のためのその使用
JP6904906B2 (ja) 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
JP6844991B2 (ja) 2015-11-10 2021-03-17 サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスSanko Tekstil Isletmeleri San. Ve Tic. A.S. ジッパーを有する伸縮性衣類の製法
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US20200061095A1 (en) * 2017-05-12 2020-02-27 Galectin Sciences, Llc Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3

Also Published As

Publication number Publication date
WO2020210308A1 (en) 2020-10-15
US20220144818A1 (en) 2022-05-12
JP2022527395A (ja) 2022-06-01
EP3953349A1 (en) 2022-02-16
KR102890853B1 (ko) 2025-11-24
KR20210150485A (ko) 2021-12-10
US12269819B2 (en) 2025-04-08
JP7577682B2 (ja) 2024-11-05

Similar Documents

Publication Publication Date Title
CN113710665A (zh) 半乳糖凝集素-3的小分子抑制剂
JP6790183B2 (ja) Ask1阻害剤の固体形態
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
TWI657071B (zh) 芳基醚及其用途
JP2023515404A (ja) ヘテロ環glp-1アゴニスト
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
CN117534685A (zh) 一种pan-KRAS抑制剂化合物
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
TWI912419B (zh) 羥肟酸酯化合物、其製備方法及其應用
TW201718561A (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
TW201609725A (zh) 作為抗癌劑之新穎三環化合物
CN105008367A (zh) 作为钾离子通道抑制剂的吡咯并三嗪类化合物
EA028821B1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
HUE035337T2 (en) Macrocyclic compounds as TRK kinase inhibitors
CN106413710A (zh) 因子XIa抑制剂
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
JP7478165B2 (ja) ガレクチン-3の低分子阻害剤
WO2020168939A1 (zh) 杂环化合物、包含其的药物组合物及其制备方法和用途
CN111433207A (zh) 作为αV整合素抑制剂的吡咯并吡嗪衍生物
CN111714628A (zh) 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
CN113336774B (zh) 作为trk抑制剂的取代的手性二芳基大环化合物
WO2020259703A1 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112292386A (zh) 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
JP7772718B2 (ja) ガレクチン-3阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination